Modality
Degrader
MOA
BETi
Target
CDK4/6
Pathway
Angiogenesis
AngelmanFabryCF
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
Apr 2022
→ Nov 2030
Phase 2Current
NCT06233066
2,243 pts·Fabry
2022-04→2030-11·Terminated
NCT04977552
2,210 pts·Fabry
2022-11→2027-03·Completed
4,453 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-01-272mo agoNDA· Fabry
2027-03-1912mo awayPh2 Data· Fabry
2030-11-134.6y awayPh2 Data· Fabry
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Termina…
P2
Complet…
Catalysts
NDA
2026-01-27 · 2mo ago
Fabry
Ph2 Data
2027-03-19 · 12mo away
Fabry
Ph2 Data
2030-11-13 · 4.6y away
Fabry
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06233066 | Phase 2 | Fabry | Terminated | 2243 | NT-proBNP |
| NCT04977552 | Phase 2 | Fabry | Completed | 2210 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-8021 | Hansoh Pharma | Approved | BTK |